Overview

A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

Status:
Completed
Trial end date:
2018-08-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the longer term safety of the study drug known as galcanezumab in participants with episodic or chronic migraine.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company